CN115531439A - 一种用于促进母猪发情的固体乳剂及其制备方法 - Google Patents
一种用于促进母猪发情的固体乳剂及其制备方法 Download PDFInfo
- Publication number
- CN115531439A CN115531439A CN202211481254.0A CN202211481254A CN115531439A CN 115531439 A CN115531439 A CN 115531439A CN 202211481254 A CN202211481254 A CN 202211481254A CN 115531439 A CN115531439 A CN 115531439A
- Authority
- CN
- China
- Prior art keywords
- extract
- solid emulsion
- sows
- promoting
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 32
- 230000012173 estrus Effects 0.000 title claims abstract description 30
- 239000007787 solid Substances 0.000 title claims abstract description 30
- 230000001737 promoting effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 45
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 32
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 18
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 17
- 239000011669 selenium Substances 0.000 claims abstract description 17
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 229940046009 vitamin E Drugs 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- 239000008213 purified water Substances 0.000 claims abstract description 13
- 239000003549 soybean oil Substances 0.000 claims abstract description 13
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003240 coconut oil Substances 0.000 claims abstract description 12
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims abstract description 11
- 235000013539 calcium stearate Nutrition 0.000 claims abstract description 11
- 239000008116 calcium stearate Substances 0.000 claims abstract description 11
- 240000007673 Origanum vulgare Species 0.000 claims abstract description 10
- 235000013628 Lantana involucrata Nutrition 0.000 claims abstract description 9
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims abstract description 9
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 9
- 239000000741 silica gel Substances 0.000 claims abstract description 9
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 9
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 8
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 8
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims abstract description 8
- 235000020696 epimedium extract Nutrition 0.000 claims abstract description 8
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 4
- 244000061520 Angelica archangelica Species 0.000 claims abstract 2
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 3
- 235000021277 colostrum Nutrition 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 241000125175 Angelica Species 0.000 description 9
- 241000207925 Leonurus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241001529744 Origanum Species 0.000 description 4
- 235000011203 Origanum Nutrition 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 2
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 2
- 235000007746 carvacrol Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- DUNMULOWUUIQIL-RGMNGODLSA-N (2s)-1,1-dimethylpyrrolidin-1-ium-2-carboxylic acid;chloride Chemical compound Cl.C[N+]1(C)CCC[C@H]1C([O-])=O DUNMULOWUUIQIL-RGMNGODLSA-N 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 235000010677 Origanum vulgare Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种用于促进母猪发情的固体乳剂及其制备方法，其组成成分及其重量为：益母草提取物3‑5g、黄芪提取物3‑5g、当归提取物3‑5g、淫羊藿提取物3‑5g、牛至香酚3‑5g、维生素E3‑5g、酵母硒0.5‑1g、纯化水20‑25g、单硬脂酸甘油脂4‑6g、椰子油或大豆油30‑35g、硬脂酸钙10‑12g、PEG4000 4‑6g、微粉硅胶15‑25g。本发明把中药提取物制备成固体乳剂，以达到更好的疗效，提高利用度，并且制备质量稳定性高，同时产品成分针对母猪不发情的本质原因进行治疗，安全有效，且无残留，无耐药性。
Description
技术领域
本发明属于中兽药领域，主要涉及一种用于促进母猪发情的固体乳剂及其制备方法。
背景技术
母猪不发情是一个很严重的情况，不发情的母猪浪费投资成本影响生产效率而近20年来每年约有五分之一的母猪因不发情被淘汰，这对养殖户产生很大的冲击。
益母草提取物，主要成分为盐酸水苏碱，具有促进动物卵巢、子宫、输卵管等生殖系统发育和增强生殖系统微循环的作用，可以兴奋子宫，促进子宫收缩和复旧，增加子宫壁厚度。
黄芪提取物，主要成分为黄芪多糖和黄芪甲苷，可以增加血液中淋巴细胞的数量，并诱导干扰素产生，同时促进肺和肠粘膜中巨噬细胞的增殖分化，显著提高机体非特异性免疫；可显著增强心肺功能；可增强细胞膜稳定性，减少应激时细胞膜通透性变化导致的机体功能紊乱，有抗应激作用；修复受损伤的免疫细胞和免疫系统，增强免疫应答。
当归提取物，补血养血，活血止痛，润燥通便。用于血虚劳伤，血瘀疼痛，跌打损伤，痈肿疮疡，肠燥便秘，胎产诸病。当归可以增强机体的免疫功能，当归中的多糖既可以激活巨噬细胞、淋巴细胞等免疫细胞，还可以增加抗体的形成，从而提高免疫机能。同时当归多糖还具有抗凝血和抗贫血的作用。
淫羊藿提取物，具有促进动物免疫器官的生长发育、对细胞免疫和体液免疫的促进作用、对自然杀伤细胞的促进作用。可以调节母猪肠道生理机能，优化肠道环境。提高母猪繁殖能力，促进动物生长。
牛至香酚，是从天然植物牛至中提取的挥发油，有香芹酚和百里香酚两种有效成分，对畜禽肠道细菌性疾病具有预防和控制作用；可以改善免疫反应，增强吞噬细菌的活性，在动物体内无残留、不产生耐药性，可在畜禽生长中长期使用。对于母猪，牛至香酚可以保护肠道健康，消除体内氧自由基。提高母猪繁殖率、降低母猪生殖系统疾病的发生。降低乳腺炎发病率，提高母猪泌乳量10%以上，并且乳猪初生重可以提高15%。
维生素E，易被饲料中的矿物质和不饱和脂肪酸氧化破坏，是一种很好的生物性抗氧化剂。在提高动物的机体免疫力，预防不孕症，促进发情，促进生长发育等发挥着重要作用。
酵母硒，对母猪的生理免疫机能也有一定程度的促进效果。可以提高血液中淋巴细胞的转化率，增加T淋巴细胞百分率，子宫内膜炎的发病率也有所降低。还可以提高繁殖力、免疫力和抗病力。
固体乳剂是以固体存在，随水相的加入而形成乳剂的分散体系。
固体乳剂的特点有以下几点：
第一，口服后遇到消化道内的体液具有自乳化的特点；
第二，能提高药物的溶解度及溶出速度，提高生物利用度，促进药物的吸收；
第三，呈干燥粉末状，粘性小，流动性好；
第四，油相被固体载体包裹，能避光和抗氧化；
第五，物理稳定性好，贮存过程中不会发生分层、破裂和转相等现象；
本发明把中药提取物制备成固体乳剂，以达到更好的疗效，提高利用度，并且制备质量稳定性高，同时产品成分针对母猪不发情的本质原因进行治疗，安全有效，且无残留，无耐药性。
发明内容
本发明的目的在于提供一种用于促进母猪发情的固体乳剂。
本发明的目的之二在于提供上述制剂的制备方法。
本发明的第三目的在于提供了上述制剂对母猪不发情的改善效果。
为实现上述目的，本发明采用如下技术方案：
一种用于促进母猪发情的固体乳剂，其组成成分及其重量为：益母草提取物3-5g、黄芪提取物3-5g、当归提取物3-5g、淫羊藿提取物3-5g、牛至香酚3-5g、维生素E3-5g、酵母硒0.5-1g、纯化水20-25g、单硬脂酸甘油脂4-6g、椰子油或大豆油30-35g、硬脂酸钙10-12g、PEG4000 4-6g、微粉硅胶15-25g。
制备方法如下：
（1）取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒溶于纯化水中；
（2）先将硬脂酸钙加入椰子油或大豆油中，再加入单硬脂酸甘油脂；
（3）在搅拌下将步骤（1）的物质加入步骤（2）中，后经过乳匀机匀化后，搅拌状态下加入PEG4000粉末，再加入微粉硅胶使初乳吸干完全，即得到本发明中的固体乳剂。
所述乳匀机的匀化时的压力为1000 Bar ~2000Bar，匀化时间为5~10分钟。
本发明饲料添加剂的使用方法：混饲，每1kg体重1g，1日1次，连用7日。
本发明具有的优点和有益效果：（1）本发明采用的制备方法简单，适合规模化生产；（2）本发明运用吸干法制备固体乳剂，达到缓释效果，提高了药物的生物利用度；（3）本发明制剂针对母猪不发情进行有效治疗；（4）本发明产品物理性质稳定，贮存和临床给药方便，适合群体给药，节省人力物力。
具体实施方式
以下通过实施对本发明做进一步的说明，但本发明的保护范围不限于此。
下述实施例中益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物均购自四川恒瑞通达生物科技有限公司，酵母硒购自安琪酵母股份有限公司
实施例1.用于促进母猪发情的固体乳剂的制备
其组成成分及其重量为：益母草提取物3g、黄芪提取物5g、当归提取物3g、淫羊藿提取物5g、牛至香酚3g、维生素E 5g、酵母硒0.5g、纯化水25g、单硬脂酸甘油脂4g、椰子油或大豆油35g、硬脂酸钙10g、PEG4000 4g、微粉硅胶23g。
制备方法如下：
（1）取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒溶于纯化水中；
（2）先将硬脂酸钙加入椰子油或大豆油中，再加入单硬脂酸甘油脂；
（3）在快速搅拌下将步骤（1）的物质缓缓加入步骤（2）中，后在乳匀机（压力为1500Bar）中匀化5分钟后，搅拌状态下加入聚乙二醇-4000粉末，再加入微粉硅胶使初乳吸干完全，即得到本发明中的固体乳剂。
实施例2.用于促进母猪发情的固体乳剂的制备
其组成成分及其重量为：益母草提取物5g、黄芪提取物3g、当归提取物5g、淫羊藿提取物3g、牛至香酚5g、维生素E3g、酵母硒1g、纯化水25g、单硬脂酸甘油脂6g、椰子油或大豆油35g、硬脂酸钙12g、PEG4000 6g、微粉硅胶16g。
制备方法如下：
（1）取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒溶于纯化水中；
（2）先将硬脂酸钙加入椰子油或大豆油中，再加入单硬脂酸甘油脂；
（3）在快速搅拌下将步骤（1）的物质缓缓加入步骤（2）中，后经过乳匀机（压力为1500Bar）匀化8分钟后，搅拌状态下加入聚乙二醇-4000粉末，再加入微粉硅胶使初乳吸干完全，即得到本发明中的固体乳剂。
实施例3.用于促进母猪发情的固体乳剂的制备
其组成成分及其重量为：益母草提取物4g、黄芪提取物4g、当归提取物4g、淫羊藿提取物4g、牛至香酚4g、维生素E4g、酵母硒0.8g、纯化水25g、单硬脂酸甘油脂5g、椰子油或大豆油32g、硬脂酸钙11g、PEG4000 5g、微粉硅胶23g。
制备方法如下：
（1）取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒溶于纯化水中；
（2）先将硬脂酸钙加入椰子油或大豆油中，再加入单硬脂酸甘油脂；
（3）在快速搅拌下将步骤（1）的物质缓缓加入步骤（2）中，后经过乳匀机（压力为1500Bar）匀化5分钟后，搅拌状态下加入聚乙二醇-4000粉末，再加入微粉硅胶使初乳吸干完全，即得到本发明中的固体乳剂。
实施例4.用于促进母猪发情的固体乳剂的对照品制备
其组成成分及其重量为：益母草提取物4g、黄芪提取物4g、当归提取物4g、淫羊藿提取物4g、牛至香酚4g、维生素E4g、酵母硒0.8g、纯化水40g、单硬脂酸甘油脂5g、吐温－802.5g、椰子油或大豆油54g。
制备方法如下：
（1）取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒及吐温－80溶于纯化水中；
（2）取单硬脂酸甘油脂溶于椰子油或大豆油中；
（3）在快速搅拌下将步骤（1）的物质缓缓加入步骤（2）中，（压力为1500Bar）匀化5分钟后，即得。
注：本对照品采用普通乳剂的制备方法制备。
实施例5.用于促进母猪发情的固体乳剂的对照品制备
其组成成分及其重量为：益母草提取物4g、黄芪提取物4g、当归提取物4g、淫羊藿提取物4g、牛至香酚4g、维生素E4g、酵母硒0.8g、葡萄糖101g。
制备方法如下：取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒、葡萄糖，置于混合机中混合均匀，即得。
注：本对照品未采用乳剂工艺制备。
实施例6.对母猪发情的影响
按照如下方法进行：
（一）药物与试剂
试验药物：实施例1、2、3所制备的中药制剂；
对照药物1：实施例4所制备的制剂
对照药物2：实施例5所制备的制剂
对照药物3：催情散（《中华人民共和国》2015年版二部）
按照如下方法进行：
（一）试验方法
（1）试验设计：选取生产母猪90头，均来自同一饲料条件下发现的发情迟缓母猪，随机分为六组，其中3个试验组、3个对照组。
3个试验组和3个对照组分别按照每天1g/kg的添加水平给药。具体方法是：采取自由采食、防疫、管理措施与日常一致，以7天为一个试验周期。
（2）观察试验结果
表1 对母猪发情影响的试验结果
本试验中，试验组的45头大多数是从治疗后4－5天开始发情，有7头没发情。
对照组1的15头大多数是从治疗后的5-7天开始发情，有5头没发情。
对照组2的15头大多数是从治疗后的5-7天开始发情，有7头没发情。
对照组3的15头大多数是从治疗后的6-7天开始发情，有7头没发情。其中有一头发情后屡配不孕。
由上表可知，本发明的固体乳剂可促进母猪发情、受孕，提高产仔数。
由此表明，本发明专利的固体乳剂工艺对促进母猪发情的药效有显著提高。
Claims (4)
1. 一种用于促进母猪发情的固体乳剂，其特征在于，其组成成分及其重量为：益母草提取物3-5g、黄芪提取物3-5g、当归提取物3-5g、淫羊藿提取物3-5g、牛至香酚3-5g、维生素E3-5g、酵母硒0.5-1g、纯化水20-25g、单硬脂酸甘油脂4-6g、椰子油或大豆油30-35g、硬脂酸钙10-12g、PEG4000 4-6g、微粉硅胶15-25g。
2.根据权利要求1所述用于促进母猪发情的固体乳剂的制备方法，其特征在于，步骤如下：
（1）取益母草提取物、黄芪提取物、当归提取物、淫羊藿提取物、牛至香酚、维生素E、酵母硒溶于纯化水中；
（2）先将硬脂酸钙加入椰子油或大豆油中，再加入单硬脂酸甘油脂；
（3）在搅拌下将步骤（1）的物质加入步骤（2）中，后经过乳匀机匀化后，搅拌状态下加入PEG4000粉末，再加入微粉硅胶使初乳吸干完全，即得到本发明中的固体乳剂。
3. 根据权利要求1所述用于促进母猪发情的固体乳剂的制备方法，其特征在于，所述乳匀机的匀化时的压力为1000 Bar ~2000Bar，匀化时间为5~10分钟。
4.根据权利要求1所述用于促进母猪发情的固体乳剂的使用方法，其特征在于，混饲，每1kg体重用1g固体乳剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211481254.0A CN115531439B (zh) | 2022-11-24 | 2022-11-24 | 一种用于促进母猪发情的固体乳剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211481254.0A CN115531439B (zh) | 2022-11-24 | 2022-11-24 | 一种用于促进母猪发情的固体乳剂及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115531439A true CN115531439A (zh) | 2022-12-30 |
| CN115531439B CN115531439B (zh) | 2024-02-02 |
Family
ID=84720440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211481254.0A Active CN115531439B (zh) | 2022-11-24 | 2022-11-24 | 一种用于促进母猪发情的固体乳剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115531439B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695482A (zh) * | 2005-06-16 | 2005-11-16 | 湖南广安生物技术有限公司 | 促母猪发情的饲料添加剂 |
| CN1739610A (zh) * | 2005-09-15 | 2006-03-01 | 闫建利 | 一种家畜催情药的天然药物组合物及其制备方法和应用 |
| CN101869221A (zh) * | 2010-06-08 | 2010-10-27 | 浙江大学 | 一种提高母猪生殖能力的饲料添加剂及其制备方法 |
-
2022
- 2022-11-24 CN CN202211481254.0A patent/CN115531439B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695482A (zh) * | 2005-06-16 | 2005-11-16 | 湖南广安生物技术有限公司 | 促母猪发情的饲料添加剂 |
| CN1739610A (zh) * | 2005-09-15 | 2006-03-01 | 闫建利 | 一种家畜催情药的天然药物组合物及其制备方法和应用 |
| CN101869221A (zh) * | 2010-06-08 | 2010-10-27 | 浙江大学 | 一种提高母猪生殖能力的饲料添加剂及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| 伟;刘晓莲;刘小华;: "牛至香酚在畜禽养殖中的应用", 中国畜牧兽医文摘, no. 11, pages 235 * |
| 明天猪价分析: "论养猪丨为什么说夏季养猪更应该使用黄芪多糖？", pages 2, Retrieved from the Internet <URL:https://baijiahao.baidu.com/s?id=1736707447036114218&wfr=spider&for=pc> * |
| 素颜: "酵母硒—硒制剂中的"战斗硒"，高效提高母猪繁殖性能", pages 1 - 3, Retrieved from the Internet <URL:https://www.feedtrade.com.cn/technology/zghzl/muzz/2015-08-28/2016275.html> * |
| 郑增娟;张建军;: "口服干乳剂研究进展", 中国实用医药, no. 04, pages 37 - 38 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115531439B (zh) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078399B (zh) | 一种兽用抗病毒纯中药制剂 | |
| CN103211801A (zh) | 一种在口腔中快速溶解的膜剂及其制备方法 | |
| CN105146228A (zh) | 用于母猪保胎的中药复方制剂及其制备方法 | |
| CN101417018A (zh) | 一种具有清热解毒、凉血止痢功能的兽用注射剂的制备方法 | |
| RU2464979C1 (ru) | Препарат для лечения и профилактики послеродового эндометрита и синдрома метрит-мастит-агалактии у свиноматок | |
| CN115531439B (zh) | 一种用于促进母猪发情的固体乳剂及其制备方法 | |
| CN101933900A (zh) | 一种用于防治禽类肝病的复方制剂及其制备方法 | |
| US20130071377A1 (en) | Composition for increasing milk production containing artemisia capillaris | |
| CN106265894A (zh) | 一种治疗畜禽细菌性腹泻的中兽药及其制备方法和用途 | |
| CN107137485A (zh) | 一种治疗猪瘟的中药注射液及其制备方法 | |
| CN112704699A (zh) | 一种治疗更年期综合征的中药组合物及其用途 | |
| CN1943554A (zh) | 一种阿维菌素透皮剂及制备方法 | |
| CN105853511B (zh) | 防治斑点叉尾鮰爱德华氏菌病的中草药药饵及其制备方法 | |
| CN113577167B (zh) | 祖师麻在制备治疗猪附红细胞体病药物中的应用 | |
| CN109464579A (zh) | 一种用于防治鸡球虫病的中药口服液及其制备方法 | |
| RU2768589C1 (ru) | Способ профилактики острого послеродового эндометрита у коров | |
| CN115887546B (zh) | 用于抗球虫的药物组合物以及用途 | |
| CN107281338B (zh) | 红葱用于治疗母猪子宫炎的用途 | |
| CN108042690B (zh) | 用于治疗猪支原体肺炎的中药组合物及其应用 | |
| CN114073728B (zh) | 一种防治蛋鸡输卵管炎的中药组合物及其制备方法 | |
| CN102697923B (zh) | 一种用于防治猪免疫抑制性疾病的中药组合物 | |
| CN108653228B (zh) | 骨架型缓释多拉菌素片剂及其制备方法 | |
| JP3177612B2 (ja) | 発酵・水解動物肝臓抽出物の製造方法、発酵・水解動物肝臓抽出物、及びそれを含有してなる製剤 | |
| CN105748742A (zh) | 一种用于畜禽痢疾的药物组合物，饲料及其制备方法 | |
| RU2091074C1 (ru) | Эмульсия для лечения метритов крупного рогатого скота (варианты) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |